Pars Plana Vitrectomy versus Intravitreal Injection of Ranibizumab in the Treatment of Diabetic Macular Edema Associated with Vitreomacular Interface Abnormalities

Table 3

Categories of CDVA change.

CDVA	Group I (n = 20)		Group II (n = 20)
	No.	%	No.	%
Improved ≥2 lines	9	(45)	6	(30)	0.351
Stable within 2 lines	11	(55)	12	(60)
Lost ≥2 lines	0	(0)	2	(10)

CDVA: corrected distance visual acuity; Group I: ranibizumab; Group II: pars plana vitrectomy; MC: Monte-Carlo correction of the chi-square test;  : value for comparing between the two studied groups.